Press Releases

13.09.2017

- Oral presentation of top-line IMPULSE data including invited expert discussion - Poster presentation of new data on lefitolimod as modulator of the tumor microenvironment alone and in combination with immune checkpoint inhibitors in pre-clinical...

05.09.2017

Berlin, 5 September 2017 – The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present two posters on its lead compound, the immunotherapeutic agent lefitolimod, at the European Society for...

25.08.2017

• Binding term sheet offers the potential to translate into a licensing deal for lefitolimod – homing in on key objective • MOLOGEN to receive upfront and milestone payments, royalties and an equity investment under the final contract • Strong...

10.08.2017

• Results from the TEACH (HIV) and IMPULSE (small cell lung cancer) clinical trials with lefitolimod • Completion of patient recruitment for the IMPALA pivotal study (colorectal cancer) • Promising results obtained from pre-clinical combination...

09.08.2017

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced the key results of the extension phase of the exploratory phase Ib/IIa TEACH trial to evaluate lefitolimod in HIV-positive (HIV:...

15.05.2017

Berlin, 15 May 2017 – The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) has achieved the recruitment goal with the inclusion of currently 540 patients for the pivotal IMPALA study in...

11.05.2017

• Ongoing implementation of the “Next Level” corporate strategy • Funding secured until the start of 2018 through additional capital measure • Further progress in clinical studies with lead product lefitolimod • Preparations for possible...

   

Displaying results 1 bis 7 von 15

Page 1

Page 2

Page 3

next

   

ESMO 2017: Positive Feedback to presentations

Press Release
Presentation

Contact:
Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50

investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.